Table 1.

Patient characteristics and GORD impact scale for the three subgroups of participation: attended the Cytosponge appointment and completed the baseline questionnaire (‘attenders’); completed the follow-up questionnaire (‘follow-up responders’) or Interviewed (‘interviewees’)

	Completed baseline questionnaire (‘attenders’) (N=1750)		Completed follow-up questionnaire (‘follow-up responders’) (N=1488)		Interviewed (‘interviewees’) (N=30)		P values for χ2 test between ‘follow-up responders’ (N=1488) and ‘attenders’ who are not ‘follow-up responders’ (N=262)
	N	%	N	%	N	%
Sex
Female	919	53	782	52	15	50	0.985
Male	830	47	706	47	15	50
Missing	1	<1	0	0	0	0
Age group
50–59	345	20	285	19	4	13	0.028*
60–69	596	34	497	33	11	35
70–79	647	37	572	38	9	29
80–99	161	9	134	9	6	19
Missing	1	<1	0	0	1	3
Cytosponge-TFF3 outcome (after repeat test)
TFF3 negative	1252	72	1126	76	14	47	0.246†
TFF3 positive	231	13	213	14	10	33
Inadequate (equivocal/low-confidence negative/technical or processing failure)	171	10	149	10	2	7
Unsuccessful swallow	96	5	0	0	4	13
Underwent repeat Cytosponge test
No	1560	89	1322	89	25	83	0.338
Yes	190	11	166	11	5	17
Education level
School up to 15–16 years of age	712	41	605	41	16	53	0.104
College or vocational school	537	31	455	31	8	27
Professional training beyond college, university graduate or postgraduate degree	480	27	414	28	4	13
Other or prefer not to say	21	1	14	1	2	7
Waist-hip ratio
<0.90	685	39	601	40	11	37	0.010*
0.90<0.99	686	39	562	38	10	33
0.99+	378	22	324	22	9	30
Missing	1	<1	1	<1	0	0
Comorbidities
No	228	13	182	12	6	20	0.018*
Yes	1522	87	1306	88	24	80
Medication duration
Less than 5 years	518	30	431	29	7	23	0.166
More than 5 years	1232	70	1057	71	23	77
Diagnoses
No Barrett’s oesophagus	1618	92	1367	92	26	87	0.118
Barrett’s oesophagus—without dysplasia	117	7	106	7	4	13
Barrett’s oesophagus—with dysplasia	11	1	11	1	0	0
Oesophageal adenocarcinoma (stage 1)	4	<1	4	<1	0	0
							P values for t-test between‘follow-up responders’ (N=1488) and ‘attenders’ who are not ‘follow-up responders’ (N=262)
GORD Impact Scale—before taking acid-suppressant medications
Mean (SD)	1.9 (0.5)		1.9 (0.5)		1.9 (0.5)		0.319
No. missing	2		1		0
GORD Impact Scale—In the last week
Mean (SD)	1.3 (0.4)		1.3 (0.4)		1.3 (0.5)		0.451
No missing	0		0		0

*P<0.05.

†Comparison excluding participants producing an unsuccessful swallow as they were not invited to fill in a follow-up questionnaire.

GORD, gastro-oesophageal reflux disease; TFF3, trefoil factor 3.